Therapeutic Potential of Naturally Occurring Small Molecules to Target the Wnt/β-Catenin Signaling Pathway in Colorectal Cancer

• Published in: Cancers 2022-01, Vol.14 (2), p.403
• Main Authors: Oliveira, Luiz F S, Predes, Danilo, Borges, Helena L, Abreu, Jose G
• Format: Article
• Language: English
• Subjects: Adenomatous polyposis coli; Adenomatous polyposis coli protein; Binding sites; Cancer; Cell cycle; Cell growth; Cell proliferation; Chemotherapy; Colorectal cancer; Colorectal carcinoma; Disease; Genes; Glycoproteins; Homeostasis; Kinases; Ligands; Medical prognosis; Metastases; Metastasis; Mutation; Patients; Phosphorylation; Proteins; Public health; Radiation therapy; Review; Signal transduction; Stem cells; Tumor microenvironment; Tumors; Wnt protein; β-Catenin
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers14020403

Colorectal cancer (CRC) ranks second in the number of cancer deaths worldwide, mainly due to late diagnoses, which restrict treatment in the potentially curable stages and decrease patient survival. The treatment of CRC involves surgery to remove the tumor tissue, in addition to radiotherapy and systemic chemotherapy sessions. However, almost half of patients are resistant to these treatments, especially in metastatic cases, where the 5-year survival rate is only 12%. This factor may be related to the intratumoral heterogeneity, tumor microenvironment (TME), and the presence of cancer stem cells (CSCs), which is impossible to resolve with the standard approaches currently available in clinical practice. CSCs are APC-deficient, and the search for alternative therapeutic agents such as small molecules from natural sources is a promising strategy, as these substances have several antitumor properties. Many of those interfere with the regulation of signaling pathways at the central core of CRC development, such as the Wnt/β-catenin, which plays a crucial role in the cell proliferation and stemness in the tumor. This review will discuss the use of naturally occurring small molecules inhibiting the Wnt/β-catenin pathway in experimental CRC models over the past decade, highlighting the molecular targets in the Wnt/β-catenin pathway and the mechanisms through which these molecules perform their antitumor activities.